Author

Yaroslav Kulyaba

Observed names: Kulyaba, Yaroslav, Y. Kulyaba

OpenAlex ID: A5085360489

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

2023 · Mustafa Özgüroğlu, Saadettin Kilickap, et al. · The Lancet Oncology · 118

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial

2024 · Mafalda Oliveira, Denys Pominchuk, et al. · The Lancet Oncology · 116

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

2024 · Christian Marth, Richard G. Moore, et al. · Journal of Clinical Oncology · 77

Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial

2023 · Mafalda Oliveira, Denys Pominchuck, et al. · Cancer Research · 64

Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial

2016 · Tadeusz Robak, Krzysztof Warzocha, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 63

Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

2025 · Saadettin Kilickap, Ana Baramidze, et al. · Journal of Thoracic Oncology · 42

PDF

Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia

2016 · Anders Österborg, Miklós Udvardy, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 27

Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial.

2023 · Mafalda Oliveira, Denys Pominchuk, et al. · Journal of Clinical Oncology · 20

2016 · Tadeusz Robak, Krzysztof Warzocha, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 11

LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

2022 · M. Özgüroğlu, S. Kilickap, et al. · Annals of Oncology · 10

PDF

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

2014 · Anders Österborg, Miklós Udvardy, et al. · Blood · 9

Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study

2025 · Shun Lu, Oleksandr Vynnychenko, et al. · The Lancet Respiratory Medicine · 5

OA11.06 Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1

2024 · S. Kilickap, A. Sezer, et al. · Journal of Thoracic Oncology · 5

PDF

2015 · Tadeusz Robak, Krzysztof Warzocha, et al. · Blood · 5

2MO Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2- metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial

2024 · M. Oliveira, E.P. Hamilton, et al. · ESMO Open · 4

PDF

Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study complement 2

2015 · Tadeusz Robak, Sebastian Grosicki, et al. · Haematologica · 4

OA01.05 Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1

2023 · M.C. Garassino, S. Kilickap, et al. · Journal of Thoracic Oncology · 3

PDF

16P: Continued cemiplimab with addition of chemotherapy beyond progression in patients with advanced NSCLC on 1L cemiplimab monotherapy: 5-year outcomes of EMPOWER-Lung 1

2025 · M.C. Garassino, A. Baramidze, et al. · Journal of Thoracic Oncology · 2

PDF

627MO POD1UM-304: Phase III study of retifanlimab plus platinum-based chemotherapy (Chemo) as first-line (1L) therapy for nonsquamous or squamous metastatic non–small cell lung cancer (mNSCLC)

2024 · S. Lu, O. Vynnychenko, et al. · Annals of Oncology · 1

Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies

2024 · Konstantin Penkov, Igor Bondarenko, et al. · Therapeutic Advances in Medical Oncology · 1

Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC)

2019 · B.C. Cho, K. Penkov, et al. · Annals of Oncology · 1

Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1

2026 · Marina Chiara Garassino, Ana Baramidze, et al. · JTO Clinical and Research Reports

72P Cemiplimab monotherapy for first-line advanced NSCLC patients with PD-L1 expression ≥50%: 6-y outcomes of EMPOWER-Lung 1

2026 · M. Gogishvili, S. Kilickap, et al. · ESMO Open

PDF

327P Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial

2022 · G.F. Ho, M. Ozguroglu, et al. · Annals of Oncology

Works count: 25

Citation count: 590

H-index: 10

I10-index: 10